Abstract
Cancer researchers are heralding the arrival of prime editing, an ultra-precise twist on CRISPR genome engineering, as a powerful new tool for disease modeling, target validation, and clinical applications.
©2019 American Association for Cancer Research.
2019
American Association for Cancer Research.
You do not currently have access to this content.